• A Blasi, J Beltran, A Pereira, and L Puig.
• Servicio de Anestesiología y Reanimación, Hospital Clínic. IDIBAPS, Barcelona, España. Electronic address: ablasi@clinic.ub.es.
• Rev Esp Anestesiol Reanim. 2015 Apr 1; 62 (4): 204-12.

AbstractCryoprecipitate is a plasma derivative rich in fibrinogen and other procoagulant factors. It has been successfully used for decades in the treatment of the coagulopathy of trauma patients, cardiovascular surgery, liver failure and disseminated intravascular coagulation. Although cryoprecipitate is routinely used in many western countries, most of the Spanish regional blood banks stopped its production in the late 1990's. Moreover, in recent years there is a movement to replace cryoprecipitate with manufactured fibrinogen concentrate. As a consequence, many of the younger anaesthesiologists did not have any direct experience with cryoprecipitate. This article aims to describe the characteristics of cryoprecipitate since it is a different product from manufactured fibrinogen concentrate, with its own specific indications that deserve to be further studied in clinical trials.Copyright © 2014 Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Publicado por Elsevier España, S.L.U. All rights reserved.

35 keywords...

hide…